Lv11
50 积分 2024-10-27 加入
OP0137 EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS/APRIL DUAL INHIBITOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED 52-WEEK STUDY
6小时前
待确认
Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial
1个月前
已完结
A human recombinant fusion protein targeting B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (April), telitacicept (RC18), in systemic lupus erythematosus (SLE): results of a phase 2b study
3个月前
已关闭
皖公网安备34019202002308
